According to tests on satisfaction towards model artificial saliva gel products in cancer patients with
damaged salivary glands as a side-effect of cancer treatments and patients with dry mouth syndrome, most patients in the target group were found to have liked the aforementioned model product. Furthermore, the Foundation has conducted clinical research in oral cancer patients and found the product capable of relieving dry mouth syndrome and presenting symptoms for patients when used for two weeks or a month, further improving acidity/alkalinity with capability to adjust the acidity/alkalinity of the oral cavity from before use if used continually for two weeks or a month. The product was found to have no effects on salivary flow rates and mold in patients’ oral cavities. The product will be developed to meet international standards for use in providing treatment for patients suffering from dry mouth syndrome and insufficient saliva.